JP Morgan Chase’s ARS Pharmaceuticals SPRY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.99M Sell
382,801
-34,289
-8% -$329K ﹤0.01% 3778
2025
Q4
$4.86M Buy
417,090
+382,031
+1,090% +$3.72M ﹤0.01% 3335
2025
Q3
$352K Buy
35,059
+499
+1% +$7.16K ﹤0.01% 5221
2025
Q2
$603K Buy
34,560
+2,357
+7% +$34K ﹤0.01% 4679
2025
Q1
$405K Buy
32,203
+1,091
+4% +$13.1K ﹤0.01% 4900
2024
Q4
$328K Sell
31,112
-1,710
-5% -$23.9K ﹤0.01% 5254
2024
Q3
$476K Sell
32,822
-178
-0.5% -$2.12K ﹤0.01% 4924
2024
Q2
$281K Sell
33,000
-17,183
-34% -$152K ﹤0.01% 4971
2024
Q1
$513K Buy
50,183
+15,534
+45% +$116K ﹤0.01% 4781
2023
Q4
$190K Buy
34,649
+369
+1% +$1.62K ﹤0.01% 5413
2023
Q3
$130K Buy
34,280
+11,746
+52% +$77.1K ﹤0.01% 5328
2023
Q2
$151K Buy
22,534
+19,612
+671% +$131K ﹤0.01% 5251
2023
Q1
$19K Buy
2,922
+350
+14% +$2.69K ﹤0.01% 5986
2022
Q4
$22K Buy
2,572
+461
+22% +$2.99K ﹤0.01% 5860
2022
Q3
$11K Buy
2,111
+614
+41% +$3.03K ﹤0.01% 5946
2022
Q2
$6K Sell
1,497
-12,261
-89% -$42.8K ﹤0.01% 6131
2022
Q1
$49K Sell
13,758
-158,066
-92% -$688K ﹤0.01% 5806
2021
Q4
$1.14M Buy
171,824
+122,174
+246% +$993K ﹤0.01% 4278
2021
Q3
$495K Buy
49,650
+40,555
+446% +$1M ﹤0.01% 4733
2021
Q2
$281K Sell
9,095
-19,255
-68% -$617K ﹤0.01% 5058
2021
Q1
$1.24M Buy
+28,350
New +$1.34M ﹤0.01% 4074

Other funds holding SPRY